Efficacy and safety of olodaterol once daily delivered via Respimat(®) in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

BACKGROUND: Olodaterol is a long-acting β(2)-agonist with a 24-hour bronchodilator profile. Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olo...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ferguson, Gary T, Feldman, Gregory J, Hofbauer, Peter, Hamilton, Alan, Allen, Lisa, Korducki, Lawrence, Sachs, Paul
פורמט: Artigo
שפה:Inglês
יצא לאור: Dove Medical Press 2014
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4064950/
https://ncbi.nlm.nih.gov/pubmed/24966672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S61717
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים